Position in ANNX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$12,917,955
-$134,045 QoQ
Shares Held
2,331,761
-10.3% QoQ
Ownership
1.17%
of shares outstanding
% of Portfolio
1.74%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ANNX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Opaleye Management Inc. holds $427,835,777 across 44 Biotechnology names. ANNX ranks #12 (3.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SLGL |
Sol-Gel Technologies Ltd.
|
500,000 | $39,610,000 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
390,000 | $32,826,300 | |
| 3 | IRON |
Disc Medicine, Inc.
|
421,000 | $26,918,740 | |
| 4 | URGN |
UroGen Pharma Ltd.
|
1,430,000 | $25,711,400 | |
| 5 | CBIO |
Crescent Biopharma, Inc.
|
1,312,615 | $24,112,737 | |
| 6 | STOK |
Stoke Therapeutics, Inc.
|
700,000 | $22,792,000 | |
| 7 | RZLT |
Rezolute, Inc.
|
6,300,000 | $19,215,000 | |
| 8 | MGTX |
MeiraGTx Holdings plc
|
2,123,259 | $18,387,422 |
All Filings in ANNX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $12,917,955 | 2,331,761 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $13,052,000 | 2,600,000 | Shares | Sole | 2026-04-13 | |
| 2025-09-30 | $7,930,000 | 2,600,000 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||